3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
91
INDUSTRY
15
NETWORK
7
NIH
4
OTHER_GOV
2
FED
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
3
Zoledronic Acid
3
enzalutamide
2
Magnetic Resonance Spectroscopy
2
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
2
Androgen Antagonists
2
Abiraterone Acetate
2
darolutamide
1
apalutamide
1
abiraterone
1
Watchful Waiting
1
Videotape Recording
1
Urination
1
Ultrasound, High-Intensity Focused, Transrectal
1
Transurethral Resection of Prostate
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Single Photon Emission Computed Tomography Computed Tomography
1
Rehabilitation
1
Radiotherapy
1
Radiosurgery
1
Prednisone
1
Prednisolone
1
Positron Emission Tomography Computed Tomography
1
Multiparametric Magnetic Resonance Imaging
1
Metformin
1
Magnetic Resonance Imaging
1
Finasteride
1
Everolimus
1
Dutasteride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Prostatic Neoplasms
×
Androgen Antagonists
×
Clear all
NCT06687421
2025-09-03
SPRINTR-REAL
Region Västerbotten
Recruiting
5,500 enrolled
NCT00268476
2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3
Active not recruiting
11,992 enrolled